Rayence Co

Rayence Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Rayence Co (228850.KQ) as of Oct 22, 2026 is 664.08 %. In the previous year, Operating Cash Flow to Debt Ratio was 804.71 % — a change of -17.48% (lower).

OCF/Debt

664.08 %

YoY

-17.48%

Last updated:

Operating Cash Flow to Debt Ratio of Rayence Co is 2024 664.08 % . Operating Cash Flow to Debt Ratio of Rayence Co was 2023 804.71 % . It decreases by -17.48% lower compared to the previous year.

The Rayence Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2017
492.38 KRW
Jan 1, 2018
909.03 KRW
Jan 1, 2019
160.88 KRW
Jan 1, 2020
398.76 KRW
Jan 1, 2021
406.55 KRW
Jan 1, 2022
618.35 KRW
Jan 1, 2023
804.71 KRW
Jan 1, 2024
664.08 KRW
The Rayence Co OCF/Debt history
YEAROCF/DebtYoY
664.08 %-17.48%
804.71 %+30.14%
618.35 %+52.10%
406.55 %+1.95%
398.76 %+147.86%
160.88 %-82.30%
909.03 %+84.62%
492.38 %+216.23%
155.70 %+181.19%
55.37 %+38.11%
40.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Operating Cash Flow to Debt Ratio of Rayence Co is 664.08 % in 2024.

Operating Cash Flow to Debt Ratio of Rayence Co changed from 804.71 % to 664.08 %, representing a -17.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Rayence Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Rayence Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Rayence Co

All Key Metrics — Rayence Co